Advertisement
Graham Hetherington has a broad range of experience in senior financialroles having most recently held positions as the Chief Financial Officer ofBacardi (2007) and Allied Domecq PLC (1999-2005). In his role at AlliedDomecq he was a key member of the team that transformed the performance,shape and reputation of Allied Domecq, doubling shareholder value andoverseeing a period of consistent earnings per share growth.
Advertisement
A Fellow of the Chartered Institute of Management Accountants (FCMA),Graham has valuable experience of leading finance functions for consumerbrand driven organisations within the food and drink industry.
As previously announced, on June 18th 2008 Shire's current ChiefFinancial Officer, Angus Russell becomes Chief Executive Officer; he willalso be acting Chief Financial Officer until 1st July, when GrahamHetherington takes up the position. On June 18th, Shire's current ChiefExecutive Officer Matthew Emmens becomes Chairman and Non-Executive Director,and Shire's current Chairman, Dr James Cavanaugh retires from the Shire Board.
Angus Russell, Shire current Chief Financial Officer commented:
"Graham brings to Shire a track record of delivering good financialresults combined with extensive strategy, M&A and corporate developmentexpertise in the rapidly changing food and drink industry."
Matthew Emmens, Shire current Chief Executive Officer added:
"We welcome Graham to the Shire Board. In addition to his contributionsas the Company's Chief Financial Officer, he brings a wealth of financialexperience as well as a new perspective from another highly competitiveindustry."
Graham Hetherington added:
"Shire stands out as a leader in its field because it has adifferentiated model, a clear strategy and it is prepared to take calculatedrisks in the interest of consistently delivering growth and shareholdervalue. I'm pleased to be joining a company with such a track record ofinnovation and I'm looking forward to bringing my experience of strongconsumer driven industries to the Shire organisation."
There are no details that are required to be disclosed under paragraph9.6.13(2-6) of the UKLA Listing Rules.
Notes to Editors
SHIRE PLC
Shire's strategic goal is to become the leading specialtybiopharmaceutical company that focuses on meeting the needs of the specialistphysician. Shire focuses its business on attention deficit and hyperactivitydisorder (ADHD), human genetic therapies (HGT), gastrointestinal (GI) andrenal diseases. The structure is sufficiently flexible to allow Shire totarget new therapeutic areas to the extent opportunities arise throughacquisitions. Shire's in-licensing, merger and acquisition efforts arefocused on products in niche markets with strong intellectual propertyprotection either in the US or Europe. Shire believes that a carefullyselected portfolio of products with strategically aligned and relativelysmall-scale sales forces will deliver strong results.
For further information on Shire, please visit the Company's website:http://www.shire.com.
"SAFE HARBOR" STATEMENT UNDER THE PRIVATE SECURITIES LITIGATION REFORMACT OF 1995
Statements included herein that are not historical facts areforward-looking statements. Such forward-looking statements involve a numberof risks and uncertainties and are subject to change at any time. In theevent such risks or uncertainties materialize, Shire's results could bematerially affected. The risks and uncertainties include, but are not limitedto, risks associated with: the inherent uncertainty of pharma
